Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Exkivity (mobocertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

EGFR inhibitor, HER2 inhibitor

Related drugs:

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

SYSA1901 (pertuzumab biosimilar) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

trastuzumab (407)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2
EGFR C797S + EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR C797S + EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: C3 – Early Trials mobocertinib Sensitive : C3	mobocertinib Sensitive: C3 – Early Trials mobocertinib Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	bevacizumab + mobocertinib Sensitive: C4 – Case Studies bevacizumab + mobocertinib Sensitive : C4	bevacizumab + mobocertinib Sensitive: C4 – Case Studies bevacizumab + mobocertinib Sensitive : C4
HER-2 exon 20G776>VC insertion	Non Small Cell Lung Cancer	HER-2 exon 20G776>VC insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D
HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D
HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma	HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical ado-trastuzumab emtansine + mobocertinib Resistant : D	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical ado-trastuzumab emtansine + mobocertinib Resistant : D
HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma	HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma	mobocertinib Resistant: D – Preclinical mobocertinib Resistant : D	mobocertinib Resistant: D – Preclinical mobocertinib Resistant : D
HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma	HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D
EGFR S768dupSVD	Non Small Cell Lung Cancer	EGFR S768dupSVD	Non Small Cell Lung Cancer	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D
EGFR A767dupASV	Non Small Cell Lung Cancer	EGFR A767dupASV	Non Small Cell Lung Cancer	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D
HER-2 T862A + HER-2 L755S	Breast Cancer	HER-2 T862A + HER-2 L755S	Breast Cancer	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D	mobocertinib Sensitive: D – Preclinical mobocertinib Sensitive : D